Skip to main content
OpenTrials
Completed

NCT Number: NCT01080157

Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes

The purpose of this research study is to test the safety and effectiveness of the SCOUT DS in measuring the concentration of substances (advanced glycation endproducts) in the skin. These substances have been found to be in higher concentrations in people with diabetes and high blood sugar. The SCOUT DS is being developed to help doctors measure these substances in skin and possibly help doctors diagnose diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Accelovance - Huntsville, Huntsville, Alabama, United States

Loading trial locations.

About this study

The trial will be a prospective, multi-center, paired data, cohort screening trial. Up to 960 subjects will complete the study to determine the relative accuracy of SCOUT DS compared to the FPG and HbA1c tests in screening for abnormal glucose tolerance. All methods will be compared to the 2 hour value of the OGTT. An algorithm utilizes skin optical modeling as well as the spectral and blood assay data accumulated from the initial phase of the study to produce a risk score for abnormal glucose tolerance. This algorithm and the calculation of the score will be integrated into the SCOUT DS for prospective testing. The design requires three patient visits to the clinical site and up to a total of seven measurements on the SCOUT device.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than or equal to 45 years; OR
  • Age 18 to 44 years and a BMI > 25 kg/m² with one or more of the following risk factors:
  • Elevated waist circumference, > 35 inches for women and >40 inches for men
  • Habitually physically inactive (does not exercise regularly)
  • Has a first-degree relative with diabetes
  • African American, Latino, Native American, Asian American, Pacific Islander
  • Has delivered a baby weighing > 9 lb or diagnosed with gestational diabetes
  • Hypertension (≥130/≥ 85 mmHg) or being treated for hypertension
  • HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
  • Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
  • Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 yrs
  • Conditions associated with insulin resistance such as acanthosis nigricans
  • History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion criteria

  • Prior participation in VL-2701
  • Receiving investigational treatments in the past 14 days
  • Psychosocial issues that interfere with an ability to follow study procedures
  • Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
  • Diagnosed with any type of diabetes, including type 1 or 2
  • Taking glucose lowering medications
  • Known to be pregnant
  • Receiving dialysis or having known renal compromise
  • Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
  • Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded Current chemotherapy, or chemotherapy within the past 12 months
  • Receiving medications that fluoresce
  • Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
  • Prior bariatric surgery

Treatment and study plan

SCOUT DS measurement

Device

Non-invasive 3-5 volar forearm scan

Primary outcomes

  1. Validation of SCOUT DS algorithm, ROC performance equivalency to FPG and A1c for detection of abnormal glucose tolerance.

    Time frame: Outcome measure is determined 2-3 months after completion of Visit 3

    The relative true positive and relative true negative fractions between the SCOUT DS and FPG tests for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL)

Secondary outcomes

  1. Receiver operator characteristic area under the curve, sensitivity, specificity, and postive & negative predictive values of the SCOUT DS, FPG, and A1C tests for detection of abnormal glucose tolerance, and the intra- & inter-day SCOUT DS test

    Time frame: Outcome measure is determined 2-3 months after completion of Visit 3

Sponsors and collaborators

Lead sponsor

VeraLight, Inc.

Industry

Registry information

Official study title

An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes

Acronym: ENGINE

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Mar 3, 2010
Registry last updated
Dec 4, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.